ClinicalTrials.gg
CompletedNCT00814944Updated Jan 10, 2013

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

A Phase 2 interventional study of Sirolimus and Sirolimus in Dry Eye, sponsored by Santen Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-10.

Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Santen Pharmaceutical Co., Ltd..

Enrollment
6th of 12
143 · median 142
Started
2009
the only one that year
Phase 2
5 of 13
none open now
Registered
2nd of 13
by date

Among the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd., this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 5 in phase 2, and was the 2nd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. is open now. The open studies under Dry Eye Syndromes, anywhere →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation compared to Placebo on the signs and symptoms of dry eye in the CAE Model.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • dry eye
  • sirolimus
  • rapamycin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria include, but are not limited to:

  • Have a reported history of dry eye in both eyes;
  • Have a history of use of or desire to use an eye drop for dry eye symptoms within the past 6 months.

Exclusion Criteria include, but are not limited to:

  • Have to the use of the study medications;
  • Have known allergy or sensitivity to the use of the study medications or diagnostic dyes;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Dose Group 1

    Drug: Sirolimus

  • Experimental
    Dose Group 2

    Drug: Sirolimus

  • Experimental
    Dose Group 3

    Drug: Sirolimus

  • Placebo comparator
    Dose Group 4

    Drug: Sirolimus

Interventions

  • Subconjunctival injection of 440 micrograms sirolimus in each eye.

    Also known as: MS-R001, rapamycin

  • Subconjunctival injection of 220 micrograms sirolimus in each eye.

    Also known as: MS-R003, rapamycin

  • Subconjunctival injection of 880 micrograms sirolimus in each eye.

    Also known as: MS-R002, rapamycin

  • Subconjunctival injection of placebo in each eye.

06

What researchers measure

Primary outcomes

  1. Mean corneal fluorescein staining (inferior region) after CAE exposure.

    Time frame: Day 28

  2. Mean ocular discomfort during CAE exposure.

    Time frame: Day 28

Secondary outcomes

  1. Safety across treatment groups.

    Time frame: Through 28 days

  2. Additional evaluations of dry eye including fluorescein staining, lissamine green staining, conjunctival redness, tear film break-up time, blink rate, ocular protection index, Schirmer's Test, and corneal sensitivity.

    Time frame: Day 28

07

Study locations

1 site
  • Ophthalmic Research Associates
    Andover, Massachusetts 01810, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2008
First posted
Dec 25, 2008
Start
Apr 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Jan 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00814944
Lead sponsor
Santen Inc.
Collaborators
MacuSight, Inc.
Responsible party
Sponsor
First posted
Dec 25, 2008
Start date
Apr 2009
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Jan 10, 2013

Study contacts

Joel Naor, MD
study director · MacuSight, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion